3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Leukemia, Myeloid, Acute
12
Multiple Myeloma
11
Recurrence
8
Lymphoma, Large B-Cell, Diffuse
4
Sarcoma
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Interventions
Cisplatin
72
Brachytherapy
31
Radiotherapy
26
Paclitaxel
23
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
21
human papillomavirus vaccine, L1 type 16, 18
20
Topotecan
18
Papillomavirus Vaccines
18
Carboplatin
18
Surveys and Questionnaires
17
Bevacizumab
16
pembrolizumab
14
Radiation
12
Gemcitabine
12
Early Intervention, Educational
12
Colposcopy
12
Methods
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
Radiotherapy, Intensity-Modulated
10
Blood Specimen Collection
10
Papanicolaou Test
9
Docetaxel
9
Vaccines, Synthetic
8
Platinum
8
Nivolumab
8
Ipilimumab
8
Counseling
8
1,2-diaminocyclohexaneplatinum II citrate
8
Vaccines
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Uterine Cervical Neoplasms
×
selinexor
×
Clear all
NCT02025985
2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2
Completed
116 enrolled
21 charts